File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Determinants for persistent fibrosis during nucleoside analogue therapy in chronic hepatitis B

TitleDeterminants for persistent fibrosis during nucleoside analogue therapy in chronic hepatitis B
Authors
Issue Date2016
PublisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0
Citation
The 25th Annual Conference of Asian Pacific Association for the Study of the Liver (APASL 2016), Tokyo, Japan, 20-24 February 2016. In Hepatology International, 2016, v. 10 n. 1 suppl., p. S239, abstract no. P-0398 How to Cite?
AbstractBACKGROUND: Changes in liver stiffness measurements (LSM) during long-term nucleoside analogue therapy in chronic hepatitis B (CHB) have not been well-investigated. METHODS: We recruited CHB patients on long-term nucleoside analogue therapy with persistent virologic suppression (HBV DNA20 IU/mL on 3 occasions of at least 6 months apart) and with previous LSM indicating significant liver fibrosis, as defined by EASL-ALEH Guidelines ([9.0 kPa for normal alanine aminotransferase [ALT] and[12.0 kPa for ALT[1–5 9 upper limit of normal). Assessment included anthropometric measurements, HBV virology, and reassessment transient elastography and controlled attenuation parameter (CAP) measurements by FibroScan (Echosens, Paris, France). Hepatic steatosis was defined as CAP C222 dB/m. RESULTS: In this interim analysis, 119 CHB patients (77.3 % male) were recruited. Mean age at reassessment and mean duration of nucleoside analogue therapy was 56.1 (±10.4) years and 8.5 (±3.1) years, respectively. 38 patients (31.9 %) had persistent liver fibrosis. Patients with persistent liver fibrosis, when compared to patients with fibrosis reversal, had a significantly higher mean body-mass index (26.0 and 23.6 kg/m2, respectively, p = 0.040), mean systolic blood pressure (144 and 136 mmHg, respectively, p = 0.029) and mean diastolic blood pressure (82 and 77 mmHg, respectively, p = 0.046). There was no significant difference in the presence of hepatic steatosis among the two groups (65.8 % and 55.6 % respectively, p = 0.290). CONCLUSION: Metabolic parameters, including body-mass index and blood pressure, could influence fibrosis reversibility during long-term nucleoside analogue therapy. Recruitment is ongoing and the influence of other metabolic parameters (e.g. metabolic syndrome) will be analyzed.
DescriptionThis journal suppl. entitled: Conference Abstracts: 25th Annual Conference of APASL, February 20–24, 2016, Tokyo, Japan
Poster Presentation: P-0398
Persistent Identifierhttp://hdl.handle.net/10722/234175
ISSN
2015 Impact Factor: 1.125
2015 SCImago Journal Rankings: 0.669

 

DC FieldValueLanguage
dc.contributor.authorSeto, WKW-
dc.contributor.authorCheung, KSM-
dc.contributor.authorLiu, SHK-
dc.contributor.authorFung, JYY-
dc.contributor.authorWong, DKH-
dc.contributor.authorLeung, WK-
dc.contributor.authorLai, CL-
dc.contributor.authorYuen, RMF-
dc.date.accessioned2016-10-14T06:59:36Z-
dc.date.available2016-10-14T06:59:36Z-
dc.date.issued2016-
dc.identifier.citationThe 25th Annual Conference of Asian Pacific Association for the Study of the Liver (APASL 2016), Tokyo, Japan, 20-24 February 2016. In Hepatology International, 2016, v. 10 n. 1 suppl., p. S239, abstract no. P-0398-
dc.identifier.issn1936-0533-
dc.identifier.urihttp://hdl.handle.net/10722/234175-
dc.descriptionThis journal suppl. entitled: Conference Abstracts: 25th Annual Conference of APASL, February 20–24, 2016, Tokyo, Japan-
dc.descriptionPoster Presentation: P-0398-
dc.description.abstractBACKGROUND: Changes in liver stiffness measurements (LSM) during long-term nucleoside analogue therapy in chronic hepatitis B (CHB) have not been well-investigated. METHODS: We recruited CHB patients on long-term nucleoside analogue therapy with persistent virologic suppression (HBV DNA20 IU/mL on 3 occasions of at least 6 months apart) and with previous LSM indicating significant liver fibrosis, as defined by EASL-ALEH Guidelines ([9.0 kPa for normal alanine aminotransferase [ALT] and[12.0 kPa for ALT[1–5 9 upper limit of normal). Assessment included anthropometric measurements, HBV virology, and reassessment transient elastography and controlled attenuation parameter (CAP) measurements by FibroScan (Echosens, Paris, France). Hepatic steatosis was defined as CAP C222 dB/m. RESULTS: In this interim analysis, 119 CHB patients (77.3 % male) were recruited. Mean age at reassessment and mean duration of nucleoside analogue therapy was 56.1 (±10.4) years and 8.5 (±3.1) years, respectively. 38 patients (31.9 %) had persistent liver fibrosis. Patients with persistent liver fibrosis, when compared to patients with fibrosis reversal, had a significantly higher mean body-mass index (26.0 and 23.6 kg/m2, respectively, p = 0.040), mean systolic blood pressure (144 and 136 mmHg, respectively, p = 0.029) and mean diastolic blood pressure (82 and 77 mmHg, respectively, p = 0.046). There was no significant difference in the presence of hepatic steatosis among the two groups (65.8 % and 55.6 % respectively, p = 0.290). CONCLUSION: Metabolic parameters, including body-mass index and blood pressure, could influence fibrosis reversibility during long-term nucleoside analogue therapy. Recruitment is ongoing and the influence of other metabolic parameters (e.g. metabolic syndrome) will be analyzed.-
dc.languageeng-
dc.publisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0-
dc.relation.ispartofHepatology International-
dc.titleDeterminants for persistent fibrosis during nucleoside analogue therapy in chronic hepatitis B-
dc.typeConference_Paper-
dc.identifier.emailSeto, WKW: wkseto@hku.hk-
dc.identifier.emailLiu, SHK: drkliu@hku.hk-
dc.identifier.emailFung, JYY: jfung@hkucc.hku.hk-
dc.identifier.emailWong, DKH: danywong@hku.hk-
dc.identifier.emailLeung, WK: waikleung@hku.hk-
dc.identifier.emailLai, CL: hrmelcl@hkucc.hku.hk-
dc.identifier.emailYuen, RMF: mfyuen@hku.hk-
dc.identifier.authoritySeto, WKW=rp01659-
dc.identifier.authorityFung, JYY=rp00518-
dc.identifier.authorityWong, DKH=rp00492-
dc.identifier.authorityLeung, WK=rp01479-
dc.identifier.authorityLai, CL=rp00314-
dc.identifier.authorityYuen, RMF=rp00479-
dc.identifier.doi10.1007/s12072-016-9707-8-
dc.identifier.hkuros267643-
dc.identifier.volume10-
dc.identifier.issue1 suppl.-
dc.identifier.spageS239, abstract no. P-0398-
dc.identifier.epageS239, abstract no. P-0398-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats